How Common Is the Growing Teratoma Syndrome in Patients With Ovarian Immature Teratoma?

Nguyen, Julie My Van; Bouchard-Fortier, Geneviève; Ferguson, Sarah E.; Covens, Allan

doi:10.1097/igc.0000000000000751

Cited by 24 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median (range) interval between the diagnosis of ovarian immature teratoma and GTS has been reported to be nine (4-55) months ( 2 ). Although approximately 100 cases have been reported in the English literature, a recent article found that GTS is more common than previously reported, with an incidence of 40% in patients who had already undergone surgery ( 3 , 4 ). Mostly, it occurs in the pelvic region but there are also some patients with extra-pelvic disease, such as lung, mediastinum, central nervous system, spleen and diaphragm ( 5 , 6 , 7 ).…”

Section: Discussionmentioning

confidence: 95%

Laparoscopic and imaging findings of growing teratoma syndrome

Taşkın

Turgay

Şükür

et al. 2021

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Growing teratoma syndrome (GTS) occurs during post-treatment observation of ovarian malignant germ cell tumors. The characteristic features of this syndrome are normal tumor marker levels and evident tumoral mass or implants on imaging studies. We report a case of GTS in a 22-year-old woman with a malignant germ cell tumor. After staging surgery and chemotherapy, computed tomography showed peritoneal implants. Laparoscopy was planned to exclude malignant recurrence. During laparoscopy, smooth and pink-colored lesions were seen at the lateral pelvic wall. Histopathologic evaluation reported mature teratoma tissue with extensive mature glial components. GTS is not a malignant condition and the benefit of radical surgical intervention in cases without mass-related complication is not proven. GTS should be kept in mind after primary treatment of ovarian immature teratoma.

show abstract

Section: Discussionmentioning

confidence: 95%

Laparoscopic and imaging findings of growing teratoma syndrome

Taşkın

Turgay

Şükür

et al. 2021

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

show abstract

“…In humans, CR (mature teratomatous metastasis) was first reported in immature ovarian teratomas [ 8 ]; this phenomenon also occurs in disseminated or metastatic foci of malignant mixed germ cell tumors of the ovary and testis [ 28 , 29 ]. CR has also been termed “transformation”, “evolution”, or “growing teratoma syndrome” [ 28 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Cisplatin induces differentiation in teratomas derived from pluripotent stem cells

Kurata

Takanashi

Ohno

et al. 2021

Regenerative Therapy

View full text Add to dashboard Cite

Introduction Currently, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can be induced to differentiate at the cellular level but not to form mature tissues or organs suitable for transplantation. ESCs/iPSCs form immature teratomas after injection into immunodeficient mice. In humans, immature teratomas often transform into fully differentiated mature teratomas after administration of anticancer agents. Methods We first investigated the ability of cisplatin to induce changes in mouse ESCs/iPSCs in vitro . Next, we designed experiments to analyze ESC/iPSC-derived immature teratoma tissue in vivo after treatment of cisplatin. Groups of six mice carrying ESC- or iPSC-derived teratomas were given either low or high dose intraperitoneal injection of cisplatin, while the control group received saline for 4 weeks. Results Treatment of ESC/iPSC cultures with cisplatin for 3 days caused a dose-related decrease in cell numbers without inducing any morphological changes to the cells. ESC/iPSC-derived teratomas showed lower growth rates with a significantly higher mature components ratio in a concentration dependent manner after cisplatin treatment (P < 0.05); however, immunohistochemical analyses demonstrated a significantly reduced PCNA labelling index and an increase in an apoptosis marker on immature neural components (P < 0.05) along with emergence of h-Caldesmon + mature smooth muscle cells in treated mice. Moreover, newly differentiated components not found in the control group, such as mature adipose tissue, cartilage, and pancreas, as well as striated muscle, salivary glands, gastric mucosa with fundic glands, and hair follicles emerged. The identities of these components were confirmed by immunostaining for specific markers. Conclusions Cisplatin has the ability to reduce immature components in ESC/iPSC-derived teratomas, presumably through apoptosis, and also to induce them to differentiate.

show abstract

“…dIscusIón Los teratomas inmaduros de ovario representan menos del 1% de los casos de cáncer de ovario, y son un tipo poco común de tumor de células germinales, afectando principalmente a muje-res jóvenes, con una edad diagnóstica promedio de 19 años. (6) En el Perú, la literatura es limitada pero se ha reportado este fenómeno en un caso de cáncer de testículo. (8) Estos casos suelen responder de manera favorable al tratamiento quirúrgico con resección total o parcial del tumor, seguido por quimioterapia con bleomicina, etopósido y cisplatino, dada su alta sensibilidad a la misma.…”

Section: Reporte De Casounclassified

“…El intervalo de presentación entre el tumor inicial y el STC varía desde 4 hasta 55 meses aproximadamente, con una mediana de 9 meses, habiendo reportes desde el segundo ciclo de quimioterapia, como hasta 12 años después el diagnóstico inicial. Sin embargo, la mayoría de los casos se presentan en los primeros dos años, por lo que la posibilidad de una recurrencia debe estar presente, como se mencionó anteriormente (6) . En el caso de nuestra paciente, la aparición de nuevas lesiones ocurrió 1 años después del fin de la quimioterapia, y la ubicación fue confinada al peritoneo.…”

Section: Reporte De Casounclassified

“…Se reporta una incidencia entre 1,9% y 11,7% en pacientes con cáncer de células germinales no seminomatoso (4)(5)(6)(7) , y se postulan diferente hipótesis con respecto a la causa de esta patología. Los principales lugares donde se localizan los tumores crecientes son la pelvis, abdomen o retroperitoneo, aunque han sido encontrados con menor frecuencia en ganglios los linfáticos y los pulmones (5) .…”

Section: Introductionunclassified

See 1 more Smart Citation

Síndrome de teratoma creciente: reporte de caso y revisión de la literatura

Alzamora

Portugal

Ortiz

et al. 2020

Rev peru ginecol obstet.

View full text Add to dashboard Cite

El síndrome de teratoma creciente (STC) es una condición infrecuente en la que se evidencia aumento de tamaño de los tumores de células germinales o la aparición de nuevas lesiones, durante o después del tratamiento con quimioterapia. Lo más característico de este tumor es la presencia exclusiva de componentes de teratoma maduro, así como valores de marcadores tumorales que negativizan durante la quimioterapia, y se mantienen negativos durante el seguimiento. Se presenta el caso de una mujer de 28 años con un tumor de ovario de células germinales mixtas sometida a cirugía y luego quimioterapia. Durante el seguimiento, desarrolló múltiples tumores pélvicos que correspondieron a teratomas maduros. En esta paciente, fue crucial identificar el síndrome de teratoma creciente para evitar tratamiento adicional con quimioterapia.

show abstract

How Common Is the Growing Teratoma Syndrome in Patients With Ovarian Immature Teratoma?

Cited by 24 publications

References 26 publications

Laparoscopic and imaging findings of growing teratoma syndrome

Laparoscopic and imaging findings of growing teratoma syndrome

Cisplatin induces differentiation in teratomas derived from pluripotent stem cells

Síndrome de teratoma creciente: reporte de caso y revisión de la literatura

Contact Info

Product

Resources

About